Statement: A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event.
Primary_evidence: Adverse Events 1:   Total: 57/57 (100.00%)   Dry eyes  13/33 (39.39%)   Heartburn  9/33 (27.27%)   Nausea after the CT (before day 7)  57/57 (100.00%)   Herpetic eruption  0/33 (0.00%)   Dry skin  15/33 (45.45%)   Alopecia  57/57 (100.00%) Adverse Events 2:   Total: 23/23 (100.00%)   Dry eyes  2/11 (18.18%)   Heartburn  2/11 (18.18%)   Nausea after the CT (before day 7)  23/23 (100.00%)   Herpetic eruption  3/11 (27.27%)   Dry skin  9/11 (81.82%)   Alopecia  23/23 (100.00%)